An immunological approach to acute myeloid leukaemia

array:24 ["pii" => "S2341287916000259" "issn" => "23412879" "doi" => "10.1016/j.anpede.2015.07.028" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1911" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2016;84:195-202" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2076 "formatos" => array:3 [ "EPUB" => 118 "HTML" => 1448 "PDF" => 510 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1695403315002830" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2015.07.004" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1911" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2016;84:195-202" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4447 "formatos" => array:3 [ "EPUB" => 110 "HTML" => 3503 "PDF" => 834 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "ORIGINAL" "titulo" => "Aspectos inmunológicos de la leucemia mieloblástica aguda" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "195" "paginaFinal" => "202" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "An immunological approach to acute myeloid leukaemia" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figura 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1343 "Ancho" => 1607 "Tamanyo" => 63888 ] ] "descripcion" => array:1 [ "es" => "Intensidad media de fluorescencia de los ligandos para los receptores inhibidores y activatorios en los blastos mieloides y linfoides. Se muestra la media y la desviación estándar de 10 leucemias agudas infantiles, 5 LMA y 5 leucemias agudas linfoblásticas. *Diferencia estadísticamente significativa." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. González, D. Bueno, P.M. Rubio, S. San Román, D. Plaza, A. Sastre, P. García-Miguel, L. Fernández, J. Valentín, I. Martínez, A. Pérez-Martínez" "autores" => array:11 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "González" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Bueno" ] 2 => array:2 [ "nombre" => "P.M." "apellidos" => "Rubio" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "San Román" ] 4 => array:2 [ "nombre" => "D." "apellidos" => "Plaza" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Sastre" ] 6 => array:2 [ "nombre" => "P." "apellidos" => "García-Miguel" ] 7 => array:2 [ "nombre" => "L." "apellidos" => "Fernández" ] 8 => array:2 [ "nombre" => "J." "apellidos" => "Valentín" ] 9 => array:2 [ "nombre" => "I." "apellidos" => "Martínez" ] 10 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Martínez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287916000259" "doi" => "10.1016/j.anpede.2015.07.028" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000259?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315002830?idApp=UINPBA00005H" "url" => "/16954033/0000008400000004/v1_201603300938/S1695403315002830/v1_201603300938/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2341287916000223" "issn" => "23412879" "doi" => "10.1016/j.anpede.2015.09.035" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1970" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2016;84:203-10" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1886 "formatos" => array:3 [ "EPUB" => 140 "HTML" => 1325 "PDF" => 421 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Chromosomal anomalies: The experience of the Congenital Anomalies Registry of the Valencia Region" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "203" "paginaFinal" => "210" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Anomalías cromosómicas: la experiencia del Registro de Anomalías Congénitas de la Comunitat Valenciana" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 943 "Ancho" => 1587 "Tamanyo" => 95868 ] ] "descripcion" => array:1 [ "en" => "Prevalence trend of total chromosomal congenital anomalies and of the principal chromosomal syndromes, Valencian Community, 2007–2011." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. Gimeno-Martos, C. Cavero-Carbonell, A. López-Maside, S. Bosch-Sánchez, C. Martos-Jiménez, O. Zurriaga" "autores" => array:6 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Gimeno-Martos" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "Cavero-Carbonell" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "López-Maside" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Bosch-Sánchez" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Martos-Jiménez" ] 5 => array:2 [ "nombre" => "O." "apellidos" => "Zurriaga" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403315003719" "doi" => "10.1016/j.anpedi.2015.09.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315003719?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000223?idApp=UINPBA00005H" "url" => "/23412879/0000008400000004/v1_201603300938/S2341287916000223/v1_201603300938/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S234128791600017X" "issn" => "23412879" "doi" => "10.1016/j.anpede.2015.06.017" "estado" => "S300" "fechaPublicacion" => "2016-04-01" "aid" => "1899" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2016;84:189-94" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1699 "formatos" => array:3 [ "EPUB" => 110 "HTML" => 1188 "PDF" => 401 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Families of the economic crisis in paediatric primary care clinics: Descriptive observational study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "189" "paginaFinal" => "194" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Las familias de la crisis en las consultas pediátricas de Atención Primaria: estudio descriptivo observacional" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Martín Martín, M. Sánchez Bayle, C. Gancedo García, M.C. Teruel de Francisco, A. Coullaut López" "autores" => array:5 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Martín Martín" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Sánchez Bayle" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Gancedo García" ] 3 => array:2 [ "nombre" => "M.C." "apellidos" => "Teruel de Francisco" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Coullaut López" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403315002404" "doi" => "10.1016/j.anpedi.2015.06.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315002404?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S234128791600017X?idApp=UINPBA00005H" "url" => "/23412879/0000008400000004/v1_201603300938/S234128791600017X/v1_201603300938/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "An immunological approach to acute myeloid leukaemia" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "195" "paginaFinal" => "202" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "B. González, D. Bueno, P.M. Rubio, S. San Román, D. Plaza, A. Sastre, P. García-Miguel, L. Fernández, J. Valentín, I. Martínez, A. Pérez-Martínez" "autores" => array:11 [ 0 => array:3 [ "nombre" => "B." "apellidos" => "González" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "D." "apellidos" => "Bueno" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "P.M." "apellidos" => "Rubio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "S." "apellidos" => "San Román" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "D." "apellidos" => "Plaza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "A." "apellidos" => "Sastre" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "P." "apellidos" => "García-Miguel" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 7 => array:3 [ "nombre" => "L." "apellidos" => "Fernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 8 => array:3 [ "nombre" => "J." "apellidos" => "Valentín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 9 => array:3 [ "nombre" => "I." "apellidos" => "Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 10 => array:4 [ "nombre" => "A." "apellidos" => "Pérez-Martínez" "email" => array:2 [ 0 => "aperezmartinez@salud.madrid.org" 1 => "antonioperezmartinez@yahoo.es" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Unidad de Hemato-Oncología Pediátrica, Hospital Universitario La Paz, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Grupo de Investigación Clínica, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Grupo de Inmunidad Innata y Cáncer, Instituto de Investigación de la Paz (IdiPaz), Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Unidad de Hemato-Oncología Pediátrica, Hospital Montepríncipe, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aspectos inmunológicos de la leucemia mieloblástica aguda" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1163 "Ancho" => 2899 "Tamanyo" => 115354 ] ] "descripcion" => array:1 [ "en" => "(a) Probability of relapse. (b) Probability of toxic death unrelated to the progression of AML." ] ] ] "textoCompleto" => "IntroductionAcute myeloid leukaemia (AML) accounts for 20% of childhood leukaemias.<a class="elsevierStyleCrossRef" href="#bib0180">1</a> Approximately 60 cases are diagnosed each year in Spain. Current therapeutic approaches are based on the administration of polychemotherapy, combining high-dose cytarabine with anthracyclines and topoisomerase inhibitors.<a class="elsevierStyleCrossRef" href="#bib0185">2</a> Furthermore, patients that respond poorly to induction therapy, patients considered to be high-risk from the outset (with secondary AML or unfavourable cytogenetic characteristics), or intermediate-risk patients that have a HLA match related donor are candidates for allogeneic haematopoietic stem cell transplantation (HSCT) for AML in first complete remission.<a class="elsevierStyleCrossRefs" href="#bib0190">3,4</a>The survival of patients with AML has improved considerably in the past 40 years, mostly due to advances in supportive care. However, survival has plateaued at 60% in recent decades. Our knowledge of the genetic heterogeneity of AML and its importance in prognosis is increasing by the day.<a class="elsevierStyleCrossRefs" href="#bib0200">5,6</a> There are cytogenetic changes that carry a good prognosis, such as t(8;21)(q22;q22), inv(16)(p13.1q22) or t(16;16)(p13.1;q22), t(15;17)(q22;q12), the presence of which corresponds to an 80% survival with chemotherapy alone, while unfavourable changes such as 5q, t(6;9)(p23;q34), monosomy 7 and complex karyotypes are refractory to chemotherapy and have survival rates of no more than 40% even with HSCT.<a class="elsevierStyleCrossRefs" href="#bib0205">6–8</a>Thus far, the potential of these genetic changes as therapeutic targets has not had a significant impact on survival.<a class="elsevierStyleCrossRefs" href="#bib0220">9,10</a> Recently, and complementing advances on genetic and epigenetic phenomena, an immunobiological approach to AML is being developed.<a class="elsevierStyleCrossRefs" href="#bib0230">11,12</a> Such an approach is supported by different observations: (a) the crucial role of HSCT<a class="elsevierStyleCrossRefs" href="#bib0190">3,13</a>; (b) the success of cellular adoptive immunotherapy with post-transplant donor lymphocyte infusions against minimal residual disease and/or mixed chimerism<a class="elsevierStyleCrossRefs" href="#bib0245">14,15</a>; and (c) the favourable clinical and preclinical experience with antibodies such as gemtuzumab ozogamicin (anti-CD33) and bi-specific T-cell engagers (CD33/CD3, AMG 330).<a class="elsevierStyleCrossRefs" href="#bib0255">16,17</a>In this regard, the Perugia group led by Dr Velardi demonstrated the antileukaemic effect of haploidentical HSCT in adult patients with AML through the donor-derived natural killer (NK) cells.<a class="elsevierStyleCrossRefs" href="#bib0265">18,19</a> Later on, the St Jude group confirmed these findings in childhood AML and pioneered an NK cell infusion regimen for consolidation therapy in patients with low-to-intermediate risk AML.<a class="elsevierStyleCrossRef" href="#bib0275">20</a> We know that the antileukaemic activity of NK cells is regulated by the recognition by inhibitory and activating receptors of their ligands in blast cells.<a class="elsevierStyleCrossRef" href="#bib0280">21</a> These ligands correspond to human leucocyte antigen class I (HLA-I) for inhibitory receptors, and major histocompatibility complex (MHC) class I-related chain A/B (MICA/B) and UL16-binding proteins 1-4 (ULBP 1-4) for activating receptors.<a class="elsevierStyleCrossRef" href="#bib0285">22</a>This study offers a retrospective review of our experience in the management of childhood AML and describes the expression of NK cell receptor ligands in 10 cases of acute leukaemia (5 myeloid and 5 lymphoid), comparing this expression in both types of acute leukaemia with the purpose of contributing additional data in support of incorporating NK cell adoptive immunotherapy to conventional chemotherapy protocols.Patients and methodsPatientsWe collected data retrospectively on the epidemiology, morphology (French-American-British [FAB] classification)<a class="elsevierStyleCrossRef" href="#bib0290">23</a> or immunological classification as proposed by the EGIL European group,<a class="elsevierStyleCrossRef" href="#bib0295">24</a> cytogenetic changes, treatment and outcomes of cases of AML diagnosed between 1996 and 2014 in the Paediatric Haemato-Oncology Unit of the Hospital Universitario La Paz in Madrid, Spain (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Patients were treated consecutively with the successive versions of the protocol developed by the Sociedad Española de Hemato-Oncología Pediátrica (Spanish Society of Paediatric Haemato-Oncology; SHOP-1996, SHOP-2001, SHOP-2007). We excluded patients with AML and Down syndrome from the analysis. We obtained the informed consent of the legal guardians of the patients prior to biological assessment, and the study was approved by the Ethics Committee of the Hospital La Paz.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Antibodies and flow cytometryWe analysed ten bone marrow aspirate samples collected at the time of diagnosis and corresponding to five patients with AML and five with acute lymphoblastic leukaemia by means of multiparametric flow cytometry with a BD FACSCanto II system. We determined the mean fluorescence intensity (MFI) of HLA-I, the ligands of the KIR inhibitory receptors in NK cells, the ligands for NK group inhibitory receptors, and MICA-B, ULBP-1, ULBP-2, ULBP-3 and ULBP-4, ligands of the NKG2D activating receptors, in leukaemic cells previously selected by size and internal complexity. We used the following antibodies: HLA-I-PE (clone: G46-2.6), manufactured by Becton, Dickinson and Company; and MICA-PE (clone: 159227), MICB-PE (clone: 236511), ULBP-1-PE (clone: 170818), ULBP-2/5/6-APC (clone: 165903), ULBP3-PE (clone: 166510) and ULBP4-PE (clone: 709116) manufactured by R&D Systems. The expression level was defined as the ratio of the mean fluorescence intensity of the tested antibodies and the measured mean autofluorescence intensity of cells.Statistical analysisWe have expressed the data as mean and standard deviation unless otherwise noted. The statistical calculations were performed with the Software Package for the Social Sciences (SPSS) version 12.0 for Windows. The event-free survival (EFS), with event defined as relapse or death, was the primary outcome variable of the study and analysed by means of the Kaplan–Meier method and the log-rank test with a 95% confidence interval. We also calculated the probability of relapse and of death unrelated to the disease (toxic death) by the same method. We used the nonparametric Mann–Whitney U test for the statistical comparison of nonparametric variables. Statistical significance was defined as P<.05.ResultsPatient characteristicsBetween 1996 and 2014, a total of 67 patients (33 male and 34 female) with a mean age of 7.2 years (range, 0–18) received a diagnosis of AML and were treated in our unit in adherence with the SHOP-1996 (30%), SHOP-2001 (25%) or SHOP-2007 (45%) protocols. The epidemiological characteristics of the patients with AML managed with the different versions of the SHOP protocol were homogeneous.In 60 patients (88%) the diagnosis was de novo AML, while 7 patients (12%) received a diagnosis of secondary AML or AML related to a myelodysplastic syndrome. <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarises the morphology and cytogenetic changes in these cases. Cytogenetic changes were found in 66% of the patients, while 34% had normal cytogenetics. Approximately one third of the patients (29%) had cytogenetic changes associated with a favourable prognosis, such as t(8;21), inv(16) and t(15;17); 20% had cytogenetic changes of unknown prognosis; and 16.5% of patients had unfavourable cytogenetic changes, MLL gene rearrangement and monosomy 7.Twenty-five patients (44%) were treated with chemotherapy alone. Twenty (30%) underwent autologous HSCT (the last one on April 30, 2012) and twenty-two patients (33%) underwent allogeneic HSCT (7 from an HLA-identical related donor, 7 from an HLA-identical unrelated donor, 4 from umbilical cord blood, and 4 from a haploidentical donor).At the time of this writing, 24 of the patients have died, 13 of them as a result of the disease and 11 due to treatment-related complications (infection in 9 patients and haemorrhage in 2). With a median followup of 26 months, the EFS of the patients with AML included in our series was 61% (95% CI, 55–67%) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>a) and the overall survival was 62% (95% CI, 56–68%). The probability of relapse was 38% (95% CI, 31–45%) and the probability of death unrelated to AML was 19% (95% CI, 14–23%) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>a and b).<elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia>Univariate analysis of event-free survivalThe univariate analysis of EFS did not reveal any differences between sex, age groups or versions of the SHOP protocol (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>b). We found significant differences in EFS between de novo AML and secondary AML (68% [95% CI, 61–75%] vs 35% [95% CI, 16–54%]), M3 AML and non-M3 AML (80% [95% CI, 68–92%] vs 57% [95% CI, 50–64%]) or presence and absence of favourable cytogenetic changes (77% [95% CI, 68–86%] vs 53% [95% CI, 45–61%]) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>c–e). The probability of relapse in patients with favourable cytogenetic changes was not significantly lower (29% vs 42%, P=.07). We did not find statistically significant differences in the probability of relapse or of toxic death between the different versions of the SHOP treatment protocol (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>The role of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemiaThe number of allogeneic HSCTs has increased significantly with the SHOP-2007 protocol compared to previous versions (SHOP-2007, 53%; SHOP-2001, 25%; SHOP-1996, 26%). Conversely, the number of autologous HSCTs has decreased with the current protocol (SHOP-2007, 15%; SHOP-2001, 58%; SHOP-1996, 46%). When we analysed the impact of HSCT on EFS, we observed a positive trend that was not statistically significant (76% [95% CI, 64–88%] vs 56% [95% CI, 48–64%]; P=.08) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>f).Expression of HLA class I and NKG2D ligands in leukemic blasts of paediatric patientsWe used multiparametric flow cytometry to measure the expression of HLA-I ligands, MICA/B and ULBP-1, ULPB-2, ULPB-3 and ULBP-4 in 10 samples of leukemic blasts analysed based on size and complexity (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). We observed that the mean fluorescence intensities of HLA-I and ULBP-4 were significantly lower in myeloid blasts than in lymphoid blasts (HLA-I, 11±3 vs 60±10 [P<.05]; ULBP-4, 5±2 vs 20±7 [P<.05]). The differences in the MFIs of MICA/B, ULBP-1, ULBP-2 and ULBP-3 were not statistically significant (<a class="elsevierStyleCrossRefs" href="#fig0015">Figs. 3 and 4</a>).<elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia>DiscussionThe results of our retrospective series are similar to those reported in studies of paediatric patients with AML both in Spain and abroad. The latest report of the Spanish Registry of Childhood Tumours (RETI) for the 1980–2013 period described an overall 5-year survival of 54% for years 1995–1999, 59% for 2000–2004 and 62% for 2005–2007. The European group NOPHO recently reported an EFS of 55% in their NOPHO-AML2004 protocol<a class="elsevierStyleCrossRef" href="#bib0300">25</a>; and the group at the St Jude's Hospital in Memphis, United States, a 5-year EFS of 63% in 230 patients during the 2000–2008 period in their AML-02 protocol.<a class="elsevierStyleCrossRef" href="#bib0305">26</a> Based on our data, the event-free survival in childhood AML has not changed substantially with the past three versions of the SHOP protocol and plateaued more than two decades ago, remaining in suboptimal values. Furthermore, consistent with the current knowledge, the survival for secondary ALM (treatment-related or arising from a myelodysplastic syndrome) is much lower than survival for de novo ALM.<a class="elsevierStyleCrossRef" href="#bib0310">27</a> On the other hand, the heterogeneity of AML is demonstrated by the EFS of promyelocytic AML (FAB M3), which far exceeds that of the rest of AMLs (80% vs 57%, P<.05), underscoring the positive impact of all-trans retinoic acid on survival and the need to find molecular targets in other types of AML.<a class="elsevierStyleCrossRef" href="#bib0315">28</a>In our series, cytogenetic changes also had an important impact on prognosis. Thus, the presence in a third of our patients of changes considered to be favourable, such as t(8;21), inv(16) or (15;17), was associated with a higher survival that was probably due to a lower probability of relapse, although this result was not statistically significant due to the small sample size. The use of allogeneic HSCT as a treatment strategy has been increasing in recent protocols, along with a decrease in autologous HSCT. Advances in cytogenetic testing methods that allow the identification of high-risk changes may have played a role in this development. We found that allogeneic HSCT was associated with an improving trend in EFS, consistent with the findings of other case series.<a class="elsevierStyleCrossRefs" href="#bib0190">3,29</a> A greater sample size may have allowed us to find significant differences in our patients.The causes of death in the patients in our series were relapse and treatment-related causes (infection and haemorrhage). The rate of toxic death has tended to decrease with successive protocols, while relapse has continued to be an important event with no change in frequency.<a class="elsevierStyleCrossRef" href="#bib0325">30</a> The small sample size of our study did not allow us to identify prognostic factors associated with the probability of relapse. We believe that a 38% relapse rate is still too high. The probability of relapse is nearly 30% in the subset of patients with favourable cytogenetics. Thus, we believe that all patients could benefit from new therapeutic approaches.In addition to this retrospective study, this article presents the preliminary results on the expression of ligands of inhibitory and activating receptors by malignant myeloid and lymphoid blasts, which we analysed with the aim of explaining the increased susceptibility of AML to NK cell cytotoxicity described by research groups in other countries.<a class="elsevierStyleCrossRef" href="#bib0330">31</a> Consistent with the existing evidence, the mean fluorescence intensities of HLA-I, ligands of the KIR inhibitory receptors, were significantly lower in myeloid than in lymphoid blasts, suggesting a greater sensitivity to NK cell cytotoxicity mediated by their inhibitory receptors. When it came to the expression of MICA/B and ULBP ligands, we only found significant differences in the expression of ULBP-4, which suggests that activating pathways play a lesser role than inhibitory pathways, consistent with the findings of other authors.<a class="elsevierStyleCrossRef" href="#bib0335">32</a> Along the same lines, it has been described that decreased expression of ligands of activating receptors in patients with AML constitutes an immune escape mechanism.<a class="elsevierStyleCrossRef" href="#bib0340">33</a> Recent research has explored haploidentical NK cell transplantation for consolidation treatment of paediatric patients with low-to-intermediate-risk AML in whom HSCT is not indicated.<a class="elsevierStyleCrossRefs" href="#bib0275">20,34</a> The results have been quite promising, with a 0% toxicity and a 100% relapse-free survival after a median followup of more than 3 years.<a class="elsevierStyleCrossRef" href="#bib0345">34</a> Biotechnology currently allows us to isolate NK cells from healthy donors by aphaeresis. Furthermore, two new cell products are currently being studied in Spain: NK cells stimulated with IL-15 obtained from haploidentical donors by aphaeresis (NK-IL-15), and activated and expanded NK cells (AENKs) from the peripheral blood of patients (autologous AENKs) or from haploidentical donors (haploidentical AENKs). To date, there is no evidence of significant toxicity in patients with advanced disease (>2 reports, based on the NCI-CTCAE v 3.0),<a class="elsevierStyleCrossRef" href="#bib0350">35</a> so this cell-based therapeutic approach could be incorporated in a national prospective multicentric study, especially in patients in remission that do not meet the criteria for allogeneic HSCT.In conclusion, the rate of HSCT in AML is still not optimal, and relapse constitutes a significant problem. Research needs to be conducted on diagnostic, therapeutic and monitoring procedures with the goal of improving on current survival. In this regard, NK cell transplantation could be an approach worth developing, considering the importance of immunological factors in AML.Conflict of interestsThe authors have no conflict of interests to declare" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres623579" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec637208" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres623580" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec637209" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Antibodies and flow cytometry" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0030" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Patient characteristics" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Univariate analysis of event-free survival" ] 2 => array:2 [ "identificador" => "sec0045" "titulo" => "The role of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia" ] 3 => array:2 [ "identificador" => "sec0050" "titulo" => "Expression of HLA class I and NKG2D ligands in leukemic blasts of paediatric patients" ] ] ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0060" "titulo" => "Conflict of interests" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-04-21" "fechaAceptado" => "2015-07-01" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec637208" "palabras" => array:5 [ 0 => "Acute myeloid leukaemia" 1 => "Natural killer cells" 2 => "Human leucocyte antigen class I (HLA-I)" 3 => "Major histocompatibility complex (MHC) class-I related chain A/B (MICA/B)" 4 => "UL16-binding proteins 1-4 (ULBP 1-4)" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec637209" "palabras" => array:5 [ 0 => "Leucemia mieloblástica aguda" 1 => "Células natural killer" 2 => "Human leucocyte antigen class I (HLA-I)" 3 => "Major histocompatibility complex (MHC) class-I related chain A/B (MICA/B)" 4 => "UL16-binding proteins 1-4 (ULBP 1-4)" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "IntroductionAcute myeloid leukaemia (AML) is the second haematological malignancy in the paediatric population, and one of the leading causes of childhood cancer mortality. Survival is currently around 60%, with no improvement in last decades, suggesting that new therapeutic approaches are needed. The anti-leukaemia effect mediated by the lymphocytes and natural killer (NK) cells of the immune system has been established in haematopoietic stem cell transplantation, and also as adoptive immunotherapy after consolidation chemotherapy schemes. Patients and methodsA retrospective study was conducted on the clinical characteristics of patients diagnosed and treated for AML in our centre from 1996 to 2014. The mean fluorescence intensities of HLA-I, MICA/B and ULBP1-4, ligands for NK cell receptors, were also analysed in ten new diagnosed leukaemia cases, five myeloid and five lymphoid. ResultsA total of 67 patients were used in this analysis. With a median follow up of 25 months, the event-free survival was 62% (95% CI: 55–67). Secondary AML, non-M3 phenotype, and the absence of favourable cytogenetic markers had a lower survival. The probability of relapse was 38% (95% CI: 31–45). The expression of HLA-I and ULBP-4 was significantly lower in myeloid than in lymphoid blast cells. ConclusionsOur clinical results are similar to those described in the literature. Survival did not significantly change in recent decades, and the likelihood of relapse remains high. Myeloid blasts might be more susceptible to the cytotoxicity of NK cells through their lower expression of HLA-I. NK therapy strategies in minimal disease situation could be effective, as reported by other groups." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "IntroducciónLa leucemia mieloblástica aguda (LMA) constituye la segunda hemopatía maligna en la población pediátrica y una de las principales causas de mortalidad por cáncer infantil. La supervivencia se sitúa alrededor del 60% sin haber mejorado en las últimas décadas, por lo que son necesarios nuevos enfoques terapéuticos. El efecto antileucémico ejercido por los linfocitos y las células natural killer (NK) del sistema inmunológico está bien establecido en el trasplante de células madre hematopoyéticas pero también como estrategia de inmunoterapia adoptiva tras la quimioterapia de consolidación. Pacientes y métodosDe manera retrospectiva, se analizan las características clínicas de los pacientes diagnosticados de LMA en nuestro centro durante el período 1996–2014. Además en 10 leucemias agudas, 5 linfoides y 5 mieloides, se analizaron la intensidad media de fluorescencia de HLA-I, MICA-B, ULBP1-4, ligandos para los receptores de las células NK. ResultadosUn total de 67 pacientes formaron parte de este análisis. La supervivencia libre de eventos con una mediana de seguimiento de 25 meses fue del 62% (IC del 95%, 55–67). Las LMA con menor supervivencia fueron las secundarias, las no M3 y las carentes de marcadores citogenéticos favorables. La probabilidad de recaída fue del 38% (IC del 95%, 31–45). La expresión de HLA-I y ULBP-4 fue significativamente menor en los blastos mieloides que en los linfoides. ConclusionesNuestros resultados clínicos son similares a los descritos en la literatura. No se ha modificado significativamente la supervivencia en las últimas décadas y la probabilidad de recaída sigue siendo elevada. Los blastos mieloides podrían ser más susceptibles a las células NK al expresar menos HLA-I, por lo que estrategias de terapia celular podrían ser eficaces tal y como reportan otros grupos." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: González B, Bueno D, Rubio PM, San Román S, Plaza D, Sastre A, et al. Aspectos inmunológicos de la leucemia mieloblástica aguda. An Pediatr (Barc). 2016;84:195–202." ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2089 "Ancho" => 3082 "Tamanyo" => 304920 ] ] "descripcion" => array:1 [ "en" => "(a) Event-free survival (death and relapse). (b) Event-free survival by SHOP protocol version. (c) Event-free survival in de novo vs secondary AML. (d) Event-free survival in M3 AML vs non-M3 AML. (e) Event-free survival in AML cases with favourable translocations t(8;21), inv(16), t(15;17) compared to other cases. (f) Event-free survival in patients that underwent allogeneic HSCT vs patients that did not." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1163 "Ancho" => 2899 "Tamanyo" => 115354 ] ] "descripcion" => array:1 [ "en" => "(a) Probability of relapse. (b) Probability of toxic death unrelated to the progression of AML." ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 2038 "Ancho" => 3122 "Tamanyo" => 206098 ] ] "descripcion" => array:1 [ "en" => "(a) Scheme for the selection of leukaemic blasts based on size, cell complexity, CD45 expression and viability. (b) Mean fluorescence intensity of ligands of inhibitory and activating receptors in myeloid and lymphoid blasts. We show the data for a single patient per group as an example. *Statistically significant difference." ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1343 "Ancho" => 1607 "Tamanyo" => 64015 ] ] "descripcion" => array:1 [ "en" => "Mean fluorescence intensity of ligands of inhibitory and activating receptors in myeloid and lymphoid blasts. We present the mean and standard deviation in 10 cases of acute childhood leukaemia, 5 of AML and 5 of acute lymphoid leukaemia. *Statistically significant difference." ] ] 4 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">67 \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Age (mean and range) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.2 (0–18) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top"><10 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38 (58.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">>10 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">27 (41.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No data \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 patients \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Sex (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33 (49) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">34 (51) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">AML (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">De novo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">60 (88) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Secondary \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (12) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Morphological classification (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 (10) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (17) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (17) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 (15) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 (8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">M7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 (20) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">EGIL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 (7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Genetic abnormalities (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (34) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">t(8;21) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 (9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">inv(16) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 (8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">t(15;17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (12) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">MLL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (15) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Monosomy 7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (1.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 (20) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Date of diagnosis (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">1996–2001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 (38.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2002–2008 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (26) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2009–2014 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (35.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No data \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 patients \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">SHOP protocol (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">1996 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18 (30) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15 (25) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2007 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">27 (45) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No data \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 patients \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">HSCT (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Autologous \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20 (30) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Allogeneic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22 (33) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No SCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 (44) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Relapse (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18 (30) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43 (70) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top">Death (%)</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">24 (35.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43 (64.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">EFS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61±6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">OS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">62±6 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1023007.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Characteristics of paediatric patients given a diagnosis of AML between 1996 and 2014 in our unit." ] ] 5 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "CI, confidence interval; ns, not significant." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-1996 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-2001 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-2007 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">P \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Relapse \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">22% (95% CI, 11–33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">32% (95% CI, 19–45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">45% (95% CI, 33–57) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.6 (ns) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Toxic death \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">33% (95% CI, 23–43) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14% (95% CI, 6–22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8% (95% CI, 6–14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">.2 (ns) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1023008.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Probability of relapse and toxic death for different versions of the SHOP protocol in our case series." ] ] 6 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Values are expressed as mean±standard deviation. The values shown in bold and italics were statistically significant." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HLA-I \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MICA/B \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MICA \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP1 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP2 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP3 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP4 \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">LLA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">60±10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16±6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13±6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15±6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">27±13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9±4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20±7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">LMA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">11±3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4±1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6±2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6±2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7±2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3±1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5±2 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1023009.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Ratio of the mean fluorescence intensity (MFI) of myeloid and lymphoid blasts. The experiment involved the analysis of 10 cases of acute leukaemia, 5 myeloid and 5 lymphoid." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:35 [ 0 => array:3 [ "identificador" => "bib0180" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pediatric acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.J. Kaspers" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/era.12.1" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Anticancer Ther" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "405" "paginaFinal" => "413" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22369331" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0185" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K. Faulk" 1 => "L. Gore" 2 => "T. Cooper" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40272-014-0067-3" "Revista" => array:6 [ "tituloSerie" => "Paediatr Drugs" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "213" "paginaFinal" => "227" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24639021" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0190" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Allogeneic hematopoietic cell transplantation for acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Vyas" 1 => "F.R. Appelbaum" 2 => "C. Craddock" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bbmt.2014.10.026" "Revista" => array:6 [ "tituloSerie" => "Biol Blood Marrow Transplant" "fecha" => "2015" "volumen" => "21" "paginaInicial" => "8" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25452033" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0195" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Lucchini" 1 => "P. Bader" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/17474086.2014.878644" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Hematol" "fecha" => "2014" "volumen" => "7" "paginaInicial" => "291" "paginaFinal" => "300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24617334" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0200" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biology, risk stratification, and therapy of pediatric acute leukemias: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.H. Pui" 1 => "W.L. Carroll" 2 => "S. Meshinchi" 3 => "R.J. Arceci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2010.30.7405" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2011" "volumen" => "29" "paginaInicial" => "551" "paginaFinal" => "565" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21220611" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0205" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advances in treatment of de-novo pediatric acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R.C. Ribeiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/CCO.0000000000000136" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Oncol" "fecha" => "2014" "volumen" => "26" "paginaInicial" => "656" "paginaFinal" => "666" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25226383" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0210" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular genetic of acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Gruber" 1 => "G. Downing" 2 => "J.R. Downing" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "Childhood Leukemias" "edicion" => "3rd ed." "serieFecha" => "2012" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0215" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.E. Karol" 1 => "E. Coustan-Smith" 2 => "X. Cao" 3 => "S.A. Shurtleff" 4 => "S.C. Raimondi" 5 => "J.K. Choi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjh.13107" "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "2015" "volumen" => "168" "paginaInicial" => "94" "paginaFinal" => "101" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25164427" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0220" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular therapeutic approaches for pediatric acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.K. Tasian" 1 => "J.A. Pollard" 2 => "R. Aplenc" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fonc.2014.00055" "Revista" => array:5 [ "tituloSerie" => "Front Oncol" "fecha" => "2014" "volumen" => "4" "paginaInicial" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24672775" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0225" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Potent inhibition of DOT1L as treatment of MLL-fusion leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.R. Daigle" 1 => "E.J. Olhava" 2 => "C.A. Therkelsen" 3 => "A. Basavapathruni" 4 => "L. Jin" 5 => "P.A. Boriack-Sjodin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2013-04-497644" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2013" "volumen" => "122" "paginaInicial" => "1017" "paginaFinal" => "1025" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23801631" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0230" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.D. Vesely" 1 => "R.D. Schreiber" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann N Y Acad Sci" "fecha" => "2013" "volumen" => "1284" "paginaInicial" => "1" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23908987" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0235" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Tettamanti" 1 => "C.F. Magnani" 2 => "A. Biondi" 3 => "E. Biagi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.imlet.2013.09.013" "Revista" => array:6 [ "tituloSerie" => "Immunol Lett" "fecha" => "2013" "volumen" => "155" "paginaInicial" => "43" "paginaFinal" => "46" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24076117" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0240" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Locatelli" 1 => "A. Bauquet" 2 => "G. Palumbo" 3 => "F. Moretta" 4 => "A. Bertaina" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.imlet.2013.09.027" "Revista" => array:6 [ "tituloSerie" => "Immunol Lett" "fecha" => "2013" "volumen" => "155" "paginaInicial" => "21" "paginaFinal" => "23" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24091162" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0245" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Rettinger" 1 => "S. Kuçi" 2 => "I. Naumann" 3 => "P. Becker" 4 => "H. Kreyenberg" 5 => "M. Anzaghe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/14653249.2011.613931" "Revista" => array:6 [ "tituloSerie" => "Cytotherapy" "fecha" => "2012" "volumen" => "14" "paginaInicial" => "91" "paginaFinal" => "103" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21973023" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0250" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Bader" 1 => "T. Klingebiel" 2 => "A. Schaudt" 3 => "U. Theurer-Mainka" 4 => "R. Handgretinger" 5 => "P. Lang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Leukemia" "fecha" => "1999" "volumen" => "13" "paginaInicial" => "2079" "paginaFinal" => "2086" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10602432" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0255" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. O’Hear" 1 => "H. Inaba" 2 => "S. Pounds" 3 => "L. Shi" 4 => "G. Dahl" 5 => "W.P. Bowman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.28334" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2013" "volumen" => "119" "paginaInicial" => "4036" "paginaFinal" => "4043" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24006085" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0260" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.S. Laszlo" 1 => "C.J. Gudgeon" 2 => "K.H. Harrington" 3 => "J. Dell’Aringa" 4 => "K.J. Newhall" 5 => "G.D. Means" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2013-09-527044" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2014" "volumen" => "123" "paginaInicial" => "554" "paginaFinal" => "561" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24311721" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0265" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Ruggeri" 1 => "A. Mancusi" 2 => "E. Burchielli" 3 => "F. Aversa" 4 => "M.F. Martelli" 5 => "A. Velardi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/14653240601078721" "Revista" => array:6 [ "tituloSerie" => "Cytotherapy" "fecha" => "2006" "volumen" => "8" "paginaInicial" => "554" "paginaFinal" => "558" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17148031" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0270" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Ruggeri" 1 => "M. Capanni" 2 => "E. Urbani" 3 => "K. Perruccio" 4 => "W.D. Shlomchik" 5 => "A. Tosti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/science.1068440" "Revista" => array:6 [ "tituloSerie" => "Science" "fecha" => "2002" "volumen" => "295" "paginaInicial" => "2097" "paginaFinal" => "2100" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11896281" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0275" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.E. Rubnitz" 1 => "H. Inaba" 2 => "R.C. Ribeiro" 3 => "S. Pounds" 4 => "B. Rooney" 5 => "T. Bell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2009.24.4590" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2010" "volumen" => "28" "paginaInicial" => "955" "paginaFinal" => "959" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20085940" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0280" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Human natural killer cells: origin, receptors, function, and clinical applications" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Moretta" 1 => "E. Montaldo" 2 => "P. Vacca" 3 => "G. Del Zotto" 4 => "F. Moretta" 5 => "P. Merli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000365632" "Revista" => array:6 [ "tituloSerie" => "Int Arch Allergy Immunol" "fecha" => "2014" "volumen" => "164" "paginaInicial" => "253" "paginaFinal" => "264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25323661" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0285" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Natural killer cells in the treatment of high-risk acute leukaemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Locatelli" 1 => "F. Moretta" 2 => "L. Brescia" 3 => "P. Merli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.smim.2014.02.004" "Revista" => array:6 [ "tituloSerie" => "Semin Immunol" "fecha" => "2014" "volumen" => "26" "paginaInicial" => "173" "paginaFinal" => "179" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24613727" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0290" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Bennett" 1 => "D. Catovsky" 2 => "M.T. Daniel" 3 => "G. Flandrin" 4 => "D.A. Galton" 5 => "H.R. Gralnick" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Haematol" "fecha" => "1976" "volumen" => "33" "paginaInicial" => "451" "paginaFinal" => "458" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/188440" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0295" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Proposals for the immunological classification of acute leukemias European Group for the Immunological Characterization of Leukemias (EGIL)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.C. Bene" 1 => "G. Castoldi" 2 => "W. Knapp" 3 => "W.D. Ludwig" 4 => "E. Matutes" 5 => "A. Orfao" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Leukemia" "fecha" => "1995" "volumen" => "9" "paginaInicial" => "1783" "paginaFinal" => "1786" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7564526" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0300" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Hasle" 1 => "J. Abrahamsson" 2 => "E. Forestier" 3 => "S.Y. Ha" 4 => "J. Heldrup" 5 => "K. Jahnukainen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2012-03-416701" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2012" "volumen" => "120" "paginaInicial" => "978" "paginaFinal" => "984" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22730539" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0305" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.E. Rubnitz" 1 => "H. Inaba" 2 => "G. Dahl" 3 => "R.C. Ribeiro" 4 => "W.P. Bowman" 5 => "J. Taub" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(10)70090-5" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "543" "paginaFinal" => "552" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20451454" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0310" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical significance of genetic aberrations in secondary acute myeloid leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.D. Milosevic" 1 => "A. Puda" 2 => "L. Malcovati" 3 => "T. Berg" 4 => "M. Hofbauer" 5 => "A. Stukalov" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ajh.23309" "Revista" => array:6 [ "tituloSerie" => "Am J Hematol" "fecha" => "2012" "volumen" => "87" "paginaInicial" => "1010" "paginaFinal" => "1016" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22887079" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0315" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding the molecular pathogenesis of acute promyelocytic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Lo-Coco" 1 => "S.K. Hasan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.beha.2014.04.006" "Revista" => array:6 [ "tituloSerie" => "Best Pract Res Clin Haematol" "fecha" => "2014" "volumen" => "27" "paginaInicial" => "3" "paginaFinal" => "9" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24907012" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0320" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Bierings" 1 => "J.B. Nachman" 2 => "C.M. Zwaan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Stem Cell Res Ther" "fecha" => "2007" "volumen" => "2" "paginaInicial" => "53" "paginaFinal" => "63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18240454" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0325" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Davila" 1 => "E. Slotkin" 2 => "T. Renaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40272-013-0048-y" "Revista" => array:6 [ "tituloSerie" => "Paediatr Drugs" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "151" "paginaFinal" => "168" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24158739" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0330" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Nanbakhsh" 1 => "C. Pochon" 2 => "A. Mallavialle" 3 => "S. Amsellem" 4 => "J.H. Bourhis" 5 => "S. Chouaib" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2013-11-536219" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2014" "volumen" => "123" "paginaInicial" => "3585" "paginaFinal" => "3595" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24677544" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0335" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Rohner" 1 => "U. Langenkamp" 2 => "U. Siegler" 3 => "C.P. Kalberer" 4 => "A. Wodnar-Filipowicz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.leukres.2007.02.020" "Revista" => array:6 [ "tituloSerie" => "Leuk Res" "fecha" => "2007" "volumen" => "31" "paginaInicial" => "1393" "paginaFinal" => "1402" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17391757" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0340" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Diermayr" 1 => "H. Himmelreich" 2 => "B. Durovic" 3 => "A. Mathys-Schneeberger" 4 => "U. Siegler" 5 => "U. Langenkamp" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1182/blood-2007-07-101311" "Revista" => array:6 [ "tituloSerie" => "Blood" "fecha" => "2008" "volumen" => "111" "paginaInicial" => "1428" "paginaFinal" => "1436" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17993609" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0345" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NK cell transplantation as consolidation therapy in children with acute myeloid leukemia-results from a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "W. Leung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/dmcn.13106" "Revista" => array:6 [ "tituloSerie" => "Macs & More" "fecha" => "2014" "volumen" => "1" "paginaInicial" => "15" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27017925" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0350" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Highlights of the third international conference on immunotherapy in pediatric oncology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Brehm" 1 => "S. Huenecke" 2 => "V. Pfirrmann" 3 => "C. Rossig" 4 => "C.L. Mackall" 5 => "C.M. Bollard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/08880018.2013.802106" "Revista" => array:6 [ "tituloSerie" => "Pediatr Hematol Oncol" "fecha" => "2013" "volumen" => "30" "paginaInicial" => "349" "paginaFinal" => "366" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23758210" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:3 [ "titulo" => "Acknowledgments" "texto" => "This study was partially funded by the Fondo de Investigación Sanitaria (FIS, project PI12/01622), and the CRIS Cancer Foundation (<a class="elsevierStyleInterRef" id="intr0010" href="http://www.criscancer.org/es/index.php">http://www.criscancer.org/es/index.php</a>)." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000008400000004/v1_201603300938/S2341287916000259/v1_201603300938/en/main.assets" "Apartado" => array:4 [ "identificador" => "26005" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000008400000004/v1_201603300938/S2341287916000259/v1_201603300938/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000259?idApp=UINPBA00005H"]

Statistics

Original Article

An immunological approach to acute myeloid leukaemia

Aspectos inmunológicos de la leucemia mieloblástica aguda

B. Gonzáleza, D. Buenoa, P.M. Rubioa, S. San Romána, D. Plazaa, A. Sastrea, P. García-Miguela, L. Fernándezb, J. Valentínc, I. Martínezd, A. Pérez-Martíneza,c,

Corresponding author

aperezmartinez@salud.madrid.org
antonioperezmartinez@yahoo.es

Corresponding author.

a Unidad de Hemato-Oncología Pediátrica, Hospital Universitario La Paz, Madrid, Spain

b Grupo de Investigación Clínica, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

c Grupo de Inmunidad Innata y Cáncer, Instituto de Investigación de la Paz (IdiPaz), Madrid, Spain

d Unidad de Hemato-Oncología Pediátrica, Hospital Montepríncipe, Madrid, Spain

Read

6251

Times
was read the article

2203

Total PDF

4048

Total HTML

Share statistics

 array:24 [
  "pii" => "S2341287916000259"
  "issn" => "23412879"
  "doi" => "10.1016/j.anpede.2015.07.028"
  "estado" => "S300"
  "fechaPublicacion" => "2016-04-01"
  "aid" => "1911"
  "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
  "copyrightAnyo" => "2015"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "An Pediatr &#40;Barc&#41;. 2016;84:195-202"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 2076
    "formatos" => array:3 [
      "EPUB" => 118
      "HTML" => 1448
      "PDF" => 510
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S1695403315002830"
      "issn" => "16954033"
      "doi" => "10.1016/j.anpedi.2015.07.004"
      "estado" => "S300"
      "fechaPublicacion" => "2016-04-01"
      "aid" => "1911"
      "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "An Pediatr &#40;Barc&#41;. 2016;84:195-202"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 4447
        "formatos" => array:3 [
          "EPUB" => 110
          "HTML" => 3503
          "PDF" => 834
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
        "titulo" => "Aspectos inmunol&#243;gicos de la leucemia mielobl&#225;stica aguda"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "195"
            "paginaFinal" => "202"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "An immunological approach to acute myeloid leukaemia"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0020"
            "etiqueta" => "Figura 4"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr4.jpeg"
                "Alto" => 1343
                "Ancho" => 1607
                "Tamanyo" => 63888
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Intensidad media de fluorescencia de los ligandos para los receptores inhibidores y activatorios en los blastos mieloides y linfoides&#46; Se muestra la media y la desviaci&#243;n est&#225;ndar de 10 leucemias agudas infantiles&#44; 5 LMA y 5 leucemias agudas linfobl&#225;sticas&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">&#42;</span>Diferencia estad&#237;sticamente significativa&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "B&#46; Gonz&#225;lez, D&#46; Bueno, P&#46;M&#46; Rubio, S&#46; San Rom&#225;n, D&#46; Plaza, A&#46; Sastre, P&#46; Garc&#237;a-Miguel, L&#46; Fern&#225;ndez, J&#46; Valent&#237;n, I&#46; Mart&#237;nez, A&#46; P&#233;rez-Mart&#237;nez"
            "autores" => array:11 [
              0 => array:2 [
                "nombre" => "B&#46;"
                "apellidos" => "Gonz&#225;lez"
              ]
              1 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Bueno"
              ]
              2 => array:2 [
                "nombre" => "P&#46;M&#46;"
                "apellidos" => "Rubio"
              ]
              3 => array:2 [
                "nombre" => "S&#46;"
                "apellidos" => "San Rom&#225;n"
              ]
              4 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Plaza"
              ]
              5 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Sastre"
              ]
              6 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Garc&#237;a-Miguel"
              ]
              7 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Fern&#225;ndez"
              ]
              8 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Valent&#237;n"
              ]
              9 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Mart&#237;nez"
              ]
              10 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "P&#233;rez-Mart&#237;nez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2341287916000259"
          "doi" => "10.1016/j.anpede.2015.07.028"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000259?idApp=UINPBA00005H"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315002830?idApp=UINPBA00005H"
      "url" => "/16954033/0000008400000004/v1_201603300938/S1695403315002830/v1_201603300938/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2341287916000223"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2015.09.035"
    "estado" => "S300"
    "fechaPublicacion" => "2016-04-01"
    "aid" => "1970"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "An Pediatr &#40;Barc&#41;. 2016;84:203-10"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1886
      "formatos" => array:3 [
        "EPUB" => 140
        "HTML" => 1325
        "PDF" => 421
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Chromosomal anomalies&#58; The experience of the Congenital Anomalies Registry of the Valencia Region"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "203"
          "paginaFinal" => "210"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Anomal&#237;as cromos&#243;micas&#58; la experiencia del Registro de Anomal&#237;as Cong&#233;nitas de la Comunitat Valenciana"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 943
              "Ancho" => 1587
              "Tamanyo" => 95868
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Prevalence trend of total chromosomal congenital anomalies and of the principal chromosomal syndromes&#44; Valencian Community&#44; 2007&#8211;2011&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S&#46; Gimeno-Martos, C&#46; Cavero-Carbonell, A&#46; L&#243;pez-Maside, S&#46; Bosch-S&#225;nchez, C&#46; Martos-Jim&#233;nez, O&#46; Zurriaga"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Gimeno-Martos"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Cavero-Carbonell"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "L&#243;pez-Maside"
            ]
            3 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Bosch-S&#225;nchez"
            ]
            4 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Martos-Jim&#233;nez"
            ]
            5 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Zurriaga"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403315003719"
        "doi" => "10.1016/j.anpedi.2015.09.010"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315003719?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000223?idApp=UINPBA00005H"
    "url" => "/23412879/0000008400000004/v1_201603300938/S2341287916000223/v1_201603300938/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S234128791600017X"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2015.06.017"
    "estado" => "S300"
    "fechaPublicacion" => "2016-04-01"
    "aid" => "1899"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "An Pediatr &#40;Barc&#41;. 2016;84:189-94"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1699
      "formatos" => array:3 [
        "EPUB" => 110
        "HTML" => 1188
        "PDF" => 401
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Families of the economic crisis in paediatric primary care clinics&#58; Descriptive observational study"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "189"
          "paginaFinal" => "194"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Las familias de la crisis en las consultas pedi&#225;tricas de Atenci&#243;n Primaria&#58; estudio descriptivo observacional"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R&#46; Mart&#237;n Mart&#237;n, M&#46; S&#225;nchez Bayle, C&#46; Gancedo Garc&#237;a, M&#46;C&#46; Teruel de Francisco, A&#46; Coullaut L&#243;pez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Mart&#237;n Mart&#237;n"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "S&#225;nchez Bayle"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Gancedo Garc&#237;a"
            ]
            3 => array:2 [
              "nombre" => "M&#46;C&#46;"
              "apellidos" => "Teruel de Francisco"
            ]
            4 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Coullaut L&#243;pez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403315002404"
        "doi" => "10.1016/j.anpedi.2015.06.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403315002404?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S234128791600017X?idApp=UINPBA00005H"
    "url" => "/23412879/0000008400000004/v1_201603300938/S234128791600017X/v1_201603300938/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
    "titulo" => "An immunological approach to acute myeloid leukaemia"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "195"
        "paginaFinal" => "202"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "B&#46; Gonz&#225;lez, D&#46; Bueno, P&#46;M&#46; Rubio, S&#46; San Rom&#225;n, D&#46; Plaza, A&#46; Sastre, P&#46; Garc&#237;a-Miguel, L&#46; Fern&#225;ndez, J&#46; Valent&#237;n, I&#46; Mart&#237;nez, A&#46; P&#233;rez-Mart&#237;nez"
        "autores" => array:11 [
          0 => array:3 [
            "nombre" => "B&#46;"
            "apellidos" => "Gonz&#225;lez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Bueno"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "P&#46;M&#46;"
            "apellidos" => "Rubio"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "S&#46;"
            "apellidos" => "San Rom&#225;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "D&#46;"
            "apellidos" => "Plaza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Sastre"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Garc&#237;a-Miguel"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Valent&#237;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Mart&#237;nez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          10 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "P&#233;rez-Mart&#237;nez"
            "email" => array:2 [
              0 => "aperezmartinez&#64;salud&#46;madrid&#46;org"
              1 => "antonioperezmartinez&#64;yahoo&#46;es"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Unidad de Hemato-Oncolog&#237;a Pedi&#225;trica&#44; Hospital Universitario La Paz&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Grupo de Investigaci&#243;n Cl&#237;nica&#44; Centro Nacional de Investigaciones Oncol&#243;gicas &#40;CNIO&#41;&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Grupo de Inmunidad Innata y C&#225;ncer&#44; Instituto de Investigaci&#243;n de la Paz &#40;IdiPaz&#41;&#44; Madrid&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Unidad de Hemato-Oncolog&#237;a Pedi&#225;trica&#44; Hospital Montepr&#237;ncipe&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Aspectos inmunol&#243;gicos de la leucemia mielobl&#225;stica aguda"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1163
            "Ancho" => 2899
            "Tamanyo" => 115354
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Probability of relapse&#46; &#40;b&#41; Probability of toxic death unrelated to the progression of AML&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Acute myeloid leukaemia &#40;AML&#41; accounts for 20&#37; of childhood leukaemias&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">1</span></a> Approximately 60 cases are diagnosed each year in Spain&#46; Current therapeutic approaches are based on the administration of polychemotherapy&#44; combining high-dose cytarabine with anthracyclines and topoisomerase inhibitors&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">2</span></a> Furthermore&#44; patients that respond poorly to induction therapy&#44; patients considered to be high-risk from the outset &#40;with secondary AML or unfavourable cytogenetic characteristics&#41;&#44; or intermediate-risk patients that have a HLA match related donor are candidates for allogeneic haematopoietic stem cell transplantation &#40;HSCT&#41; for AML in first complete remission&#46;<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">3&#44;4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The survival of patients with AML has improved considerably in the past 40 years&#44; mostly due to advances in supportive care&#46; However&#44; survival has plateaued at 60&#37; in recent decades&#46; Our knowledge of the genetic heterogeneity of AML and its importance in prognosis is increasing by the day&#46;<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">5&#44;6</span></a> There are cytogenetic changes that carry a good prognosis&#44; such as t&#40;8&#59;21&#41;&#40;q22&#59;q22&#41;&#44; inv&#40;16&#41;&#40;p13&#46;1q22&#41; or t&#40;16&#59;16&#41;&#40;p13&#46;1&#59;q22&#41;&#44; t&#40;15&#59;17&#41;&#40;q22&#59;q12&#41;&#44; the presence of which corresponds to an 80&#37; survival with chemotherapy alone&#44; while unfavourable changes such as 5q&#44; t&#40;6&#59;9&#41;&#40;p23&#59;q34&#41;&#44; monosomy 7 and complex karyotypes are refractory to chemotherapy and have survival rates of no more than 40&#37; even with HSCT&#46;<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">6&#8211;8</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Thus far&#44; the potential of these genetic changes as therapeutic targets has not had a significant impact on survival&#46;<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">9&#44;10</span></a> Recently&#44; and complementing advances on genetic and epigenetic phenomena&#44; an immunobiological approach to AML is being developed&#46;<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">11&#44;12</span></a> Such an approach is supported by different observations&#58; &#40;a&#41; the crucial role of HSCT<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">3&#44;13</span></a>&#59; &#40;b&#41; the success of cellular adoptive immunotherapy with post-transplant donor lymphocyte infusions against minimal residual disease and&#47;or mixed chimerism<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">14&#44;15</span></a>&#59; and &#40;c&#41; the favourable clinical and preclinical experience with antibodies such as gemtuzumab ozogamicin &#40;anti-CD33&#41; and bi-specific T-cell engagers &#40;CD33&#47;CD3&#44; AMG 330&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">16&#44;17</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In this regard&#44; the Perugia group led by Dr Velardi demonstrated the antileukaemic effect of haploidentical HSCT in adult patients with AML through the donor-derived natural killer &#40;NK&#41; cells&#46;<a class="elsevierStyleCrossRefs" href="#bib0265"><span class="elsevierStyleSup">18&#44;19</span></a> Later on&#44; the St Jude group confirmed these findings in childhood AML and pioneered an NK cell infusion regimen for consolidation therapy in patients with low-to-intermediate risk AML&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">20</span></a> We know that the antileukaemic activity of NK cells is regulated by the recognition by inhibitory and activating receptors of their ligands in blast cells&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">21</span></a> These ligands correspond to human leucocyte antigen class I &#40;HLA-I&#41; for inhibitory receptors&#44; and major histocompatibility complex &#40;MHC&#41; class I-related chain A&#47;B &#40;MICA&#47;B&#41; and UL16-binding proteins 1-4 &#40;ULBP 1-4&#41; for activating receptors&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">22</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">This study offers a retrospective review of our experience in the management of childhood AML and describes the expression of NK cell receptor ligands in 10 cases of acute leukaemia &#40;5 myeloid and 5 lymphoid&#41;&#44; comparing this expression in both types of acute leukaemia with the purpose of contributing additional data in support of incorporating NK cell adoptive immunotherapy to conventional chemotherapy protocols&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients</span><p id="par0030" class="elsevierStylePara elsevierViewall">We collected data retrospectively on the epidemiology&#44; morphology &#40;French-American-British &#91;FAB&#93; classification&#41;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">23</span></a> or immunological classification as proposed by the EGIL European group&#44;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">24</span></a> cytogenetic changes&#44; treatment and outcomes of cases of AML diagnosed between 1996 and 2014 in the Paediatric Haemato-Oncology Unit of the Hospital Universitario La Paz in Madrid&#44; Spain &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Patients were treated consecutively with the successive versions of the protocol developed by the Sociedad Espa&#241;ola de Hemato-Oncolog&#237;a Pedi&#225;trica &#40;Spanish Society of Paediatric Haemato-Oncology&#59; SHOP-1996&#44; SHOP-2001&#44; SHOP-2007&#41;&#46; We excluded patients with AML and Down syndrome from the analysis&#46; We obtained the informed consent of the legal guardians of the patients prior to biological assessment&#44; and the study was approved by the Ethics Committee of the Hospital La Paz&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Antibodies and flow cytometry</span><p id="par0035" class="elsevierStylePara elsevierViewall">We analysed ten bone marrow aspirate samples collected at the time of diagnosis and corresponding to five patients with AML and five with acute lymphoblastic leukaemia by means of multiparametric flow cytometry with a BD FACSCanto II system&#46; We determined the mean fluorescence intensity &#40;MFI&#41; of HLA-I&#44; the ligands of the KIR inhibitory receptors in NK cells&#44; the ligands for NK group inhibitory receptors&#44; and MICA-B&#44; ULBP-1&#44; ULBP-2&#44; ULBP-3 and ULBP-4&#44; ligands of the NKG2D activating receptors&#44; in leukaemic cells previously selected by size and internal complexity&#46; We used the following antibodies&#58; HLA-I-PE &#40;clone&#58; G46-2&#46;6&#41;&#44; manufactured by Becton&#44; Dickinson and Company&#59; and MICA-PE &#40;clone&#58; 159227&#41;&#44; MICB-PE &#40;clone&#58; 236511&#41;&#44; ULBP-1-PE &#40;clone&#58; 170818&#41;&#44; ULBP-2&#47;5&#47;6-APC &#40;clone&#58; 165903&#41;&#44; ULBP3-PE &#40;clone&#58; 166510&#41; and ULBP4-PE &#40;clone&#58; 709116&#41; manufactured by R&#38;D Systems&#46; The expression level was defined as the ratio of the mean fluorescence intensity of the tested antibodies and the measured mean autofluorescence intensity of cells&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0040" class="elsevierStylePara elsevierViewall">We have expressed the data as mean and standard deviation unless otherwise noted&#46; The statistical calculations were performed with the Software Package for the Social Sciences &#40;SPSS&#41; version 12&#46;0 for Windows&#46; The event-free survival &#40;EFS&#41;&#44; with event defined as relapse or death&#44; was the primary outcome variable of the study and analysed by means of the Kaplan&#8211;Meier method and the log-rank test with a 95&#37; confidence interval&#46; We also calculated the probability of relapse and of death unrelated to the disease &#40;toxic death&#41; by the same method&#46; We used the nonparametric Mann&#8211;Whitney <span class="elsevierStyleItalic">U</span> test for the statistical comparison of nonparametric variables&#46; Statistical significance was defined as <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Patient characteristics</span><p id="par0045" class="elsevierStylePara elsevierViewall">Between 1996 and 2014&#44; a total of 67 patients &#40;33 male and 34 female&#41; with a mean age of 7&#46;2 years &#40;range&#44; 0&#8211;18&#41; received a diagnosis of AML and were treated in our unit in adherence with the SHOP-1996 &#40;30&#37;&#41;&#44; SHOP-2001 &#40;25&#37;&#41; or SHOP-2007 &#40;45&#37;&#41; protocols&#46; The epidemiological characteristics of the patients with AML managed with the different versions of the SHOP protocol were homogeneous&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">In 60 patients &#40;88&#37;&#41; the diagnosis was de novo AML&#44; while 7 patients &#40;12&#37;&#41; received a diagnosis of secondary AML or AML related to a myelodysplastic syndrome&#46; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarises the morphology and cytogenetic changes in these cases&#46; Cytogenetic changes were found in 66&#37; of the patients&#44; while 34&#37; had normal cytogenetics&#46; Approximately one third of the patients &#40;29&#37;&#41; had cytogenetic changes associated with a favourable prognosis&#44; such as t&#40;8&#59;21&#41;&#44; inv&#40;16&#41; and t&#40;15&#59;17&#41;&#59; 20&#37; had cytogenetic changes of unknown prognosis&#59; and 16&#46;5&#37; of patients had unfavourable cytogenetic changes&#44; MLL gene rearrangement and monosomy 7&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Twenty-five patients &#40;44&#37;&#41; were treated with chemotherapy alone&#46; Twenty &#40;30&#37;&#41; underwent autologous HSCT &#40;the last one on April 30&#44; 2012&#41; and twenty-two patients &#40;33&#37;&#41; underwent allogeneic HSCT &#40;7 from an HLA-identical related donor&#44; 7 from an HLA-identical unrelated donor&#44; 4 from umbilical cord blood&#44; and 4 from a haploidentical donor&#41;&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">At the time of this writing&#44; 24 of the patients have died&#44; 13 of them as a result of the disease and 11 due to treatment-related complications &#40;infection in 9 patients and haemorrhage in 2&#41;&#46; With a median followup of 26 months&#44; the EFS of the patients with AML included in our series was 61&#37; &#40;95&#37; CI&#44; 55&#8211;67&#37;&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>a&#41; and the overall survival was 62&#37; &#40;95&#37; CI&#44; 56&#8211;68&#37;&#41;&#46; The probability of relapse was 38&#37; &#40;95&#37; CI&#44; 31&#8211;45&#37;&#41; and the probability of death unrelated to AML was 19&#37; &#40;95&#37; CI&#44; 14&#8211;23&#37;&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>a and b&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Univariate analysis of event-free survival</span><p id="par0065" class="elsevierStylePara elsevierViewall">The univariate analysis of EFS did not reveal any differences between sex&#44; age groups or versions of the SHOP protocol &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>b&#41;&#46; We found significant differences in EFS between de novo AML and secondary AML &#40;68&#37; &#91;95&#37; CI&#44; 61&#8211;75&#37;&#93; vs 35&#37; &#91;95&#37; CI&#44; 16&#8211;54&#37;&#93;&#41;&#44; M3 AML and non-M3 AML &#40;80&#37; &#91;95&#37; CI&#44; 68&#8211;92&#37;&#93; vs 57&#37; &#91;95&#37; CI&#44; 50&#8211;64&#37;&#93;&#41; or presence and absence of favourable cytogenetic changes &#40;77&#37; &#91;95&#37; CI&#44; 68&#8211;86&#37;&#93; vs 53&#37; &#91;95&#37; CI&#44; 45&#8211;61&#37;&#93;&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>c&#8211;e&#41;&#46; The probability of relapse in patients with favourable cytogenetic changes was not significantly lower &#40;29&#37; vs 42&#37;&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;07&#41;&#46; We did not find statistically significant differences in the probability of relapse or of toxic death between the different versions of the SHOP treatment protocol &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">The role of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia</span><p id="par0070" class="elsevierStylePara elsevierViewall">The number of allogeneic HSCTs has increased significantly with the SHOP-2007 protocol compared to previous versions &#40;SHOP-2007&#44; 53&#37;&#59; SHOP-2001&#44; 25&#37;&#59; SHOP-1996&#44; 26&#37;&#41;&#46; Conversely&#44; the number of autologous HSCTs has decreased with the current protocol &#40;SHOP-2007&#44; 15&#37;&#59; SHOP-2001&#44; 58&#37;&#59; SHOP-1996&#44; 46&#37;&#41;&#46; When we analysed the impact of HSCT on EFS&#44; we observed a positive trend that was not statistically significant &#40;76&#37; &#91;95&#37; CI&#44; 64&#8211;88&#37;&#93; vs 56&#37; &#91;95&#37; CI&#44; 48&#8211;64&#37;&#93;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;08&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>f&#41;&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Expression of HLA class I and NKG2D ligands in leukemic blasts of paediatric patients</span><p id="par0075" class="elsevierStylePara elsevierViewall">We used multiparametric flow cytometry to measure the expression of HLA-I ligands&#44; MICA&#47;B and ULBP-1&#44; ULPB-2&#44; ULPB-3 and ULBP-4 in 10 samples of leukemic blasts analysed based on size and complexity &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; We observed that the mean fluorescence intensities of HLA-I and ULBP-4 were significantly lower in myeloid blasts than in lymphoid blasts &#40;HLA-I&#44; 11<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3 vs 60<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>10 &#91;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#93;&#59; ULBP-4&#44; 5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2 vs 20<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>7 &#91;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#93;&#41;&#46; The differences in the MFIs of MICA&#47;B&#44; ULBP-1&#44; ULBP-2 and ULBP-3 were not statistically significant &#40;<a class="elsevierStyleCrossRefs" href="#fig0015">Figs&#46; 3 and 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">The results of our retrospective series are similar to those reported in studies of paediatric patients with AML both in Spain and abroad&#46; The latest report of the Spanish Registry of Childhood Tumours &#40;RETI&#41; for the 1980&#8211;2013 period described an overall 5-year survival of 54&#37; for years 1995&#8211;1999&#44; 59&#37; for 2000&#8211;2004 and 62&#37; for 2005&#8211;2007&#46; The European group NOPHO recently reported an EFS of 55&#37; in their NOPHO-AML2004 protocol<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">25</span></a>&#59; and the group at the St Jude&#39;s Hospital in Memphis&#44; United States&#44; a 5-year EFS of 63&#37; in 230 patients during the 2000&#8211;2008 period in their AML-02 protocol&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">26</span></a> Based on our data&#44; the event-free survival in childhood AML has not changed substantially with the past three versions of the SHOP protocol and plateaued more than two decades ago&#44; remaining in suboptimal values&#46; Furthermore&#44; consistent with the current knowledge&#44; the survival for secondary ALM &#40;treatment-related or arising from a myelodysplastic syndrome&#41; is much lower than survival for de novo ALM&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">27</span></a> On the other hand&#44; the heterogeneity of AML is demonstrated by the EFS of promyelocytic AML &#40;FAB M3&#41;&#44; which far exceeds that of the rest of AMLs &#40;80&#37; vs 57&#37;&#44; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#41;&#44; underscoring the positive impact of all-trans retinoic acid on survival and the need to find molecular targets in other types of AML&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">28</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">In our series&#44; cytogenetic changes also had an important impact on prognosis&#46; Thus&#44; the presence in a third of our patients of changes considered to be favourable&#44; such as t&#40;8&#59;21&#41;&#44; inv&#40;16&#41; or &#40;15&#59;17&#41;&#44; was associated with a higher survival that was probably due to a lower probability of relapse&#44; although this result was not statistically significant due to the small sample size&#46; The use of allogeneic HSCT as a treatment strategy has been increasing in recent protocols&#44; along with a decrease in autologous HSCT&#46; Advances in cytogenetic testing methods that allow the identification of high-risk changes may have played a role in this development&#46; We found that allogeneic HSCT was associated with an improving trend in EFS&#44; consistent with the findings of other case series&#46;<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">3&#44;29</span></a> A greater sample size may have allowed us to find significant differences in our patients&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">The causes of death in the patients in our series were relapse and treatment-related causes &#40;infection and haemorrhage&#41;&#46; The rate of toxic death has tended to decrease with successive protocols&#44; while relapse has continued to be an important event with no change in frequency&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">30</span></a> The small sample size of our study did not allow us to identify prognostic factors associated with the probability of relapse&#46; We believe that a 38&#37; relapse rate is still too high&#46; The probability of relapse is nearly 30&#37; in the subset of patients with favourable cytogenetics&#46; Thus&#44; we believe that all patients could benefit from new therapeutic approaches&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">In addition to this retrospective study&#44; this article presents the preliminary results on the expression of ligands of inhibitory and activating receptors by malignant myeloid and lymphoid blasts&#44; which we analysed with the aim of explaining the increased susceptibility of AML to NK cell cytotoxicity described by research groups in other countries&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">31</span></a> Consistent with the existing evidence&#44; the mean fluorescence intensities of HLA-I&#44; ligands of the KIR inhibitory receptors&#44; were significantly lower in myeloid than in lymphoid blasts&#44; suggesting a greater sensitivity to NK cell cytotoxicity mediated by their inhibitory receptors&#46; When it came to the expression of MICA&#47;B and ULBP ligands&#44; we only found significant differences in the expression of ULBP-4&#44; which suggests that activating pathways play a lesser role than inhibitory pathways&#44; consistent with the findings of other authors&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">32</span></a> Along the same lines&#44; it has been described that decreased expression of ligands of activating receptors in patients with AML constitutes an immune escape mechanism&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">33</span></a> Recent research has explored haploidentical NK cell transplantation for consolidation treatment of paediatric patients with low-to-intermediate-risk AML in whom HSCT is not indicated&#46;<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">20&#44;34</span></a> The results have been quite promising&#44; with a 0&#37; toxicity and a 100&#37; relapse-free survival after a median followup of more than 3 years&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">34</span></a> Biotechnology currently allows us to isolate NK cells from healthy donors by aphaeresis&#46; Furthermore&#44; two new cell products are currently being studied in Spain&#58; NK cells stimulated with IL-15 obtained from haploidentical donors by aphaeresis &#40;NK-IL-15&#41;&#44; and activated and expanded NK cells &#40;AENKs&#41; from the peripheral blood of patients &#40;autologous AENKs&#41; or from haploidentical donors &#40;haploidentical AENKs&#41;&#46; To date&#44; there is no evidence of significant toxicity in patients with advanced disease &#40;&#62;2 reports&#44; based on the NCI-CTCAE v 3&#46;0&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">35</span></a> so this cell-based therapeutic approach could be incorporated in a national prospective multicentric study&#44; especially in patients in remission that do not meet the criteria for allogeneic HSCT&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">In conclusion&#44; the rate of HSCT in AML is still not optimal&#44; and relapse constitutes a significant problem&#46; Research needs to be conducted on diagnostic&#44; therapeutic and monitoring procedures with the goal of improving on current survival&#46; In this regard&#44; NK cell transplantation could be an approach worth developing&#44; considering the importance of immunological factors in AML&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of interests</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors have no conflict of interests to declare</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:10 [
        0 => array:3 [
          "identificador" => "xres623579"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Patients and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec637208"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres623580"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Introducci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Pacientes y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec637209"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Patients and methods"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Patients"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Antibodies and flow cytometry"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0030"
          "titulo" => "Results"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Patient characteristics"
            ]
            1 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Univariate analysis of event-free survival"
            ]
            2 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "The role of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia"
            ]
            3 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Expression of HLA class I and NKG2D ligands in leukemic blasts of paediatric patients"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conflict of interests"
        ]
        9 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2015-04-21"
    "fechaAceptado" => "2015-07-01"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec637208"
          "palabras" => array:5 [
            0 => "Acute myeloid leukaemia"
            1 => "Natural killer cells"
            2 => "Human leucocyte antigen class I &#40;HLA-I&#41;"
            3 => "Major histocompatibility complex &#40;MHC&#41; class-I related chain A&#47;B &#40;MICA&#47;B&#41;"
            4 => "UL16-binding proteins 1-4 &#40;ULBP 1-4&#41;"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec637209"
          "palabras" => array:5 [
            0 => "Leucemia mielobl&#225;stica aguda"
            1 => "C&#233;lulas natural killer"
            2 => "Human leucocyte antigen class I &#40;HLA-I&#41;"
            3 => "Major histocompatibility complex &#40;MHC&#41; class-I related chain A&#47;B &#40;MICA&#47;B&#41;"
            4 => "UL16-binding proteins 1-4 &#40;ULBP 1-4&#41;"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Acute myeloid leukaemia &#40;AML&#41; is the second haematological malignancy in the paediatric population&#44; and one of the leading causes of childhood cancer mortality&#46; Survival is currently around 60&#37;&#44; with no improvement in last decades&#44; suggesting that new therapeutic approaches are needed&#46; The anti-leukaemia effect mediated by the lymphocytes and natural killer &#40;NK&#41; cells of the immune system has been established in haematopoietic stem cell transplantation&#44; and also as adoptive immunotherapy after consolidation chemotherapy schemes&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A retrospective study was conducted on the clinical characteristics of patients diagnosed and treated for AML in our centre from 1996 to 2014&#46; The mean fluorescence intensities of HLA-I&#44; MICA&#47;B and ULBP1-4&#44; ligands for NK cell receptors&#44; were also analysed in ten new diagnosed leukaemia cases&#44; five myeloid and five lymphoid&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A total of 67 patients were used in this analysis&#46; With a median follow up of 25 months&#44; the event-free survival was 62&#37; &#40;95&#37; CI&#58; 55&#8211;67&#41;&#46; Secondary AML&#44; non-M3 phenotype&#44; and the absence of favourable cytogenetic markers had a lower survival&#46; The probability of relapse was 38&#37; &#40;95&#37; CI&#58; 31&#8211;45&#41;&#46; The expression of HLA-I and ULBP-4 was significantly lower in myeloid than in lymphoid blast cells&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Our clinical results are similar to those described in the literature&#46; Survival did not significantly change in recent decades&#44; and the likelihood of relapse remains high&#46; Myeloid blasts might be more susceptible to the cytotoxicity of NK cells through their lower expression of HLA-I&#46; NK therapy strategies in minimal disease situation could be effective&#44; as reported by other groups&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Patients and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducci&#243;n</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La leucemia mielobl&#225;stica aguda &#40;LMA&#41; constituye la segunda hemopat&#237;a maligna en la poblaci&#243;n pedi&#225;trica y una de las principales causas de mortalidad por c&#225;ncer infantil&#46; La supervivencia se sit&#250;a alrededor del 60&#37; sin haber mejorado en las &#250;ltimas d&#233;cadas&#44; por lo que son necesarios nuevos enfoques terap&#233;uticos&#46; El efecto antileuc&#233;mico ejercido por los linfocitos y las c&#233;lulas natural killer &#40;NK&#41; del sistema inmunol&#243;gico est&#225; bien establecido en el trasplante de c&#233;lulas madre hematopoy&#233;ticas pero tambi&#233;n como estrategia de inmunoterapia adoptiva tras la quimioterapia de consolidaci&#243;n&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y m&#233;todos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">De manera retrospectiva&#44; se analizan las caracter&#237;sticas cl&#237;nicas de los pacientes diagnosticados de LMA en nuestro centro durante el per&#237;odo 1996&#8211;2014&#46; Adem&#225;s en 10 leucemias agudas&#44; 5 linfoides y 5 mieloides&#44; se analizaron la intensidad media de fluorescencia de HLA-I&#44; MICA-B&#44; ULBP1-4&#44; ligandos para los receptores de las c&#233;lulas NK&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Un total de 67 pacientes formaron parte de este an&#225;lisis&#46; La supervivencia libre de eventos con una mediana de seguimiento de 25 meses fue del 62&#37; &#40;IC del 95&#37;&#44; 55&#8211;67&#41;&#46; Las LMA con menor supervivencia fueron las secundarias&#44; las no M3 y las carentes de marcadores citogen&#233;ticos favorables&#46; La probabilidad de reca&#237;da fue del 38&#37; &#40;IC del 95&#37;&#44; 31&#8211;45&#41;&#46; La expresi&#243;n de HLA-I y ULBP-4 fue significativamente menor en los blastos mieloides que en los linfoides&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Nuestros resultados cl&#237;nicos son similares a los descritos en la literatura&#46; No se ha modificado significativamente la supervivencia en las &#250;ltimas d&#233;cadas y la probabilidad de reca&#237;da sigue siendo elevada&#46; Los blastos mieloides podr&#237;an ser m&#225;s susceptibles a las c&#233;lulas NK al expresar menos HLA-I&#44; por lo que estrategias de terapia celular podr&#237;an ser eficaces tal y como reportan otros grupos&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Introducci&#243;n"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Pacientes y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Gonz&#225;lez B&#44; Bueno D&#44; Rubio PM&#44; San Rom&#225;n S&#44; Plaza D&#44; Sastre A&#44; et al&#46; Aspectos inmunol&#243;gicos de la leucemia mielobl&#225;stica aguda&#46; An Pediatr &#40;Barc&#41;&#46; 2016&#59;84&#58;195&#8211;202&#46;</p>"
      ]
    ]
    "multimedia" => array:7 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2089
            "Ancho" => 3082
            "Tamanyo" => 304920
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Event-free survival &#40;death and relapse&#41;&#46; &#40;b&#41; Event-free survival by SHOP protocol version&#46; &#40;c&#41; Event-free survival in de novo vs secondary AML&#46; &#40;d&#41; Event-free survival in M3 AML vs non-M3 AML&#46; &#40;e&#41; Event-free survival in AML cases with favourable translocations t&#40;8&#59;21&#41;&#44; inv&#40;16&#41;&#44; t&#40;15&#59;17&#41; compared to other cases&#46; &#40;f&#41; Event-free survival in patients that underwent allogeneic HSCT vs patients that did not&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1163
            "Ancho" => 2899
            "Tamanyo" => 115354
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Probability of relapse&#46; &#40;b&#41; Probability of toxic death unrelated to the progression of AML&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2038
            "Ancho" => 3122
            "Tamanyo" => 206098
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Scheme for the selection of leukaemic blasts based on size&#44; cell complexity&#44; CD45 expression and viability&#46; &#40;b&#41; Mean fluorescence intensity of ligands of inhibitory and activating receptors in myeloid and lymphoid blasts&#46; We show the data for a single patient per group as an example&#46; &#42;Statistically significant difference&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1343
            "Ancho" => 1607
            "Tamanyo" => 64015
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Mean fluorescence intensity of ligands of inhibitory and activating receptors in myeloid and lymphoid blasts&#46; We present the mean and standard deviation in 10 cases of acute childhood leukaemia&#44; 5 of AML and 5 of acute lymphoid leukaemia&#46;</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">&#42;Statistically significant difference&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">N</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Age &#40;mean and range&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;2 &#40;0&#8211;18&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#60;10 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">38 &#40;58&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#62;10 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">27 &#40;41&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No data&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Sex &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">33 &#40;49&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">34 &#40;51&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">AML &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>De novo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">60 &#40;88&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Secondary&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7 &#40;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Morphological classification &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">9 &#40;15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12 &#40;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>EGIL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 &#40;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Genetic abnormalities &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23 &#40;34&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>t&#40;8&#59;21&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 &#40;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>inv&#40;16&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>t&#40;15&#59;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8 &#40;12&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>MLL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10 &#40;15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Monosomy 7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 &#40;1&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14 &#40;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Date of diagnosis &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1996&#8211;2001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25 &#40;38&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>2002&#8211;2008&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17 &#40;26&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>2009&#8211;2014&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23 &#40;35&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No data&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">SHOP protocol &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1996&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">18 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>2001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15 &#40;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>2007&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">27 &#40;45&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No data&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7 patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">HSCT &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Autologous&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">20 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Allogeneic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22 &#40;33&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No SCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">25 &#40;44&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Relapse &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">18 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">43 &#40;70&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Death &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">24 &#40;35&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">43 &#40;64&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>EFS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">61<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>OS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">62<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1023007.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Characteristics of paediatric patients given a diagnosis of AML between 1996 and 2014 in our unit&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">CI&#44; confidence interval&#59; ns&#44; not significant&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-1996&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-2001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SHOP-2007&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Relapse&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">22&#37; &#40;95&#37; CI&#44; 11&#8211;33&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">32&#37; &#40;95&#37; CI&#44; 19&#8211;45&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">45&#37; &#40;95&#37; CI&#44; 33&#8211;57&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#46;6 &#40;ns&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Toxic death&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">33&#37; &#40;95&#37; CI&#44; 23&#8211;43&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&#37; &#40;95&#37; CI&#44; 6&#8211;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">8&#37; &#40;95&#37; CI&#44; 6&#8211;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#46;2 &#40;ns&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1023008.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Probability of relapse and toxic death for different versions of the SHOP protocol in our case series&#46;</p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Values are expressed as mean<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>standard deviation&#46; The values shown in bold and italics were statistically significant&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HLA-I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MICA&#47;B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">MICA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ULBP4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">LLA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">60</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">&#177;</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">10</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">15<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">27<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">9<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">20</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">&#177;</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">7</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">LMA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">11</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">&#177;</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">3</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">5</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">&#177;</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic"><span class="elsevierStyleBold">2</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1023009.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Ratio of the mean fluorescence intensity &#40;MFI&#41; of myeloid and lymphoid blasts&#46; The experiment involved the analysis of 10 cases of acute leukaemia&#44; 5 myeloid and 5 lymphoid&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:35 [
            0 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pediatric acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46;J&#46; Kaspers"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/era.12.1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Anticancer Ther"
                        "fecha" => "2012"
                        "volumen" => "12"
                        "paginaInicial" => "405"
                        "paginaFinal" => "413"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22369331"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Faulk"
                            1 => "L&#46; Gore"
                            2 => "T&#46; Cooper"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40272-014-0067-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Paediatr Drugs"
                        "fecha" => "2014"
                        "volumen" => "16"
                        "paginaInicial" => "213"
                        "paginaFinal" => "227"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24639021"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Allogeneic hematopoietic cell transplantation for acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "P&#46; Vyas"
                            1 => "F&#46;R&#46; Appelbaum"
                            2 => "C&#46; Craddock"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.bbmt.2014.10.026"
                      "Revista" => array:6 [
                        "tituloSerie" => "Biol Blood Marrow Transplant"
                        "fecha" => "2015"
                        "volumen" => "21"
                        "paginaInicial" => "8"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25452033"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia&#58; an open challenge"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46; Lucchini"
                            1 => "P&#46; Bader"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/17474086.2014.878644"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Hematol"
                        "fecha" => "2014"
                        "volumen" => "7"
                        "paginaInicial" => "291"
                        "paginaFinal" => "300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24617334"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biology&#44; risk stratification&#44; and therapy of pediatric acute leukemias&#58; an update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "C&#46;H&#46; Pui"
                            1 => "W&#46;L&#46; Carroll"
                            2 => "S&#46; Meshinchi"
                            3 => "R&#46;J&#46; Arceci"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2010.30.7405"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2011"
                        "volumen" => "29"
                        "paginaInicial" => "551"
                        "paginaFinal" => "565"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21220611"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Advances in treatment of de-novo pediatric acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46;C&#46; Ribeiro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/CCO.0000000000000136"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Oncol"
                        "fecha" => "2014"
                        "volumen" => "26"
                        "paginaInicial" => "656"
                        "paginaFinal" => "666"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25226383"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Molecular genetic of acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Gruber"
                            1 => "G&#46; Downing"
                            2 => "J&#46;R&#46; Downing"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:3 [
                        "titulo" => "Childhood Leukemias"
                        "edicion" => "3rd ed&#46;"
                        "serieFecha" => "2012"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;E&#46; Karol"
                            1 => "E&#46; Coustan-Smith"
                            2 => "X&#46; Cao"
                            3 => "S&#46;A&#46; Shurtleff"
                            4 => "S&#46;C&#46; Raimondi"
                            5 => "J&#46;K&#46; Choi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjh.13107"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "2015"
                        "volumen" => "168"
                        "paginaInicial" => "94"
                        "paginaFinal" => "101"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25164427"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Molecular therapeutic approaches for pediatric acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;K&#46; Tasian"
                            1 => "J&#46;A&#46; Pollard"
                            2 => "R&#46; Aplenc"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fonc.2014.00055"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Oncol"
                        "fecha" => "2014"
                        "volumen" => "4"
                        "paginaInicial" => "55"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24672775"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potent inhibition of DOT1L as treatment of MLL-fusion leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;R&#46; Daigle"
                            1 => "E&#46;J&#46; Olhava"
                            2 => "C&#46;A&#46; Therkelsen"
                            3 => "A&#46; Basavapathruni"
                            4 => "L&#46; Jin"
                            5 => "P&#46;A&#46; Boriack-Sjodin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2013-04-497644"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2013"
                        "volumen" => "122"
                        "paginaInicial" => "1017"
                        "paginaFinal" => "1025"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23801631"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer immunoediting&#58; antigens&#44; mechanisms&#44; and implications to cancer immunotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;D&#46; Vesely"
                            1 => "R&#46;D&#46; Schreiber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann N Y Acad Sci"
                        "fecha" => "2013"
                        "volumen" => "1284"
                        "paginaInicial" => "1"
                        "paginaFinal" => "5"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23908987"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute myeloid leukemia and novel biological treatments&#58; monoclonal antibodies and cell-based gene-modified immune effectors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Tettamanti"
                            1 => "C&#46;F&#46; Magnani"
                            2 => "A&#46; Biondi"
                            3 => "E&#46; Biagi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.imlet.2013.09.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunol Lett"
                        "fecha" => "2013"
                        "volumen" => "155"
                        "paginaInicial" => "43"
                        "paginaFinal" => "46"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24076117"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Negative depletion of &#945;&#47;&#946;&#43; T cells and of CD19&#43; B lymphocytes&#58; a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "F&#46; Locatelli"
                            1 => "A&#46; Bauquet"
                            2 => "G&#46; Palumbo"
                            3 => "F&#46; Moretta"
                            4 => "A&#46; Bertaina"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.imlet.2013.09.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunol Lett"
                        "fecha" => "2013"
                        "volumen" => "155"
                        "paginaInicial" => "21"
                        "paginaFinal" => "23"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24091162"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Rettinger"
                            1 => "S&#46; Ku&#231;i"
                            2 => "I&#46; Naumann"
                            3 => "P&#46; Becker"
                            4 => "H&#46; Kreyenberg"
                            5 => "M&#46; Anzaghe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/14653249.2011.613931"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cytotherapy"
                        "fecha" => "2012"
                        "volumen" => "14"
                        "paginaInicial" => "91"
                        "paginaFinal" => "103"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21973023"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism&#58; a single center experience of 12 children"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Bader"
                            1 => "T&#46; Klingebiel"
                            2 => "A&#46; Schaudt"
                            3 => "U&#46; Theurer-Mainka"
                            4 => "R&#46; Handgretinger"
                            5 => "P&#46; Lang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia"
                        "fecha" => "1999"
                        "volumen" => "13"
                        "paginaInicial" => "2079"
                        "paginaFinal" => "2086"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10602432"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; O&#8217;Hear"
                            1 => "H&#46; Inaba"
                            2 => "S&#46; Pounds"
                            3 => "L&#46; Shi"
                            4 => "G&#46; Dahl"
                            5 => "W&#46;P&#46; Bowman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.28334"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2013"
                        "volumen" => "119"
                        "paginaInicial" => "4036"
                        "paginaFinal" => "4043"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24006085"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cellular determinants for preclinical activity of a novel CD33&#47;CD3 bispecific T-cell engager &#40;BiTE&#41; antibody&#44; AMG 330&#44; against human AML"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;S&#46; Laszlo"
                            1 => "C&#46;J&#46; Gudgeon"
                            2 => "K&#46;H&#46; Harrington"
                            3 => "J&#46; Dell&#8217;Aringa"
                            4 => "K&#46;J&#46; Newhall"
                            5 => "G&#46;D&#46; Means"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2013-09-527044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2014"
                        "volumen" => "123"
                        "paginaInicial" => "554"
                        "paginaFinal" => "561"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24311721"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "L&#46; Ruggeri"
                            1 => "A&#46; Mancusi"
                            2 => "E&#46; Burchielli"
                            3 => "F&#46; Aversa"
                            4 => "M&#46;F&#46; Martelli"
                            5 => "A&#46; Velardi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/14653240601078721"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cytotherapy"
                        "fecha" => "2006"
                        "volumen" => "8"
                        "paginaInicial" => "554"
                        "paginaFinal" => "558"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17148031"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Ruggeri"
                            1 => "M&#46; Capanni"
                            2 => "E&#46; Urbani"
                            3 => "K&#46; Perruccio"
                            4 => "W&#46;D&#46; Shlomchik"
                            5 => "A&#46; Tosti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1126/science.1068440"
                      "Revista" => array:6 [
                        "tituloSerie" => "Science"
                        "fecha" => "2002"
                        "volumen" => "295"
                        "paginaInicial" => "2097"
                        "paginaFinal" => "2100"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11896281"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "NKAML&#58; a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;E&#46; Rubnitz"
                            1 => "H&#46; Inaba"
                            2 => "R&#46;C&#46; Ribeiro"
                            3 => "S&#46; Pounds"
                            4 => "B&#46; Rooney"
                            5 => "T&#46; Bell"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2009.24.4590"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2010"
                        "volumen" => "28"
                        "paginaInicial" => "955"
                        "paginaFinal" => "959"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20085940"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Human natural killer cells&#58; origin&#44; receptors&#44; function&#44; and clinical applications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Moretta"
                            1 => "E&#46; Montaldo"
                            2 => "P&#46; Vacca"
                            3 => "G&#46; Del Zotto"
                            4 => "F&#46; Moretta"
                            5 => "P&#46; Merli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000365632"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol"
                        "fecha" => "2014"
                        "volumen" => "164"
                        "paginaInicial" => "253"
                        "paginaFinal" => "264"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25323661"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Natural killer cells in the treatment of high-risk acute leukaemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "F&#46; Locatelli"
                            1 => "F&#46; Moretta"
                            2 => "L&#46; Brescia"
                            3 => "P&#46; Merli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.smim.2014.02.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Immunol"
                        "fecha" => "2014"
                        "volumen" => "26"
                        "paginaInicial" => "173"
                        "paginaFinal" => "179"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24613727"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Proposals for the classification of the acute leukaemias French-American-British &#40;FAB&#41; co-operative group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Bennett"
                            1 => "D&#46; Catovsky"
                            2 => "M&#46;T&#46; Daniel"
                            3 => "G&#46; Flandrin"
                            4 => "D&#46;A&#46; Galton"
                            5 => "H&#46;R&#46; Gralnick"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Haematol"
                        "fecha" => "1976"
                        "volumen" => "33"
                        "paginaInicial" => "451"
                        "paginaFinal" => "458"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/188440"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Proposals for the immunological classification of acute leukemias European Group for the Immunological Characterization of Leukemias &#40;EGIL&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;C&#46; Bene"
                            1 => "G&#46; Castoldi"
                            2 => "W&#46; Knapp"
                            3 => "W&#46;D&#46; Ludwig"
                            4 => "E&#46; Matutes"
                            5 => "A&#46; Orfao"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia"
                        "fecha" => "1995"
                        "volumen" => "9"
                        "paginaInicial" => "1783"
                        "paginaFinal" => "1786"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7564526"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML&#58; results from NOPHO-AML 2004"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46; Hasle"
                            1 => "J&#46; Abrahamsson"
                            2 => "E&#46; Forestier"
                            3 => "S&#46;Y&#46; Ha"
                            4 => "J&#46; Heldrup"
                            5 => "K&#46; Jahnukainen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2012-03-416701"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2012"
                        "volumen" => "120"
                        "paginaInicial" => "978"
                        "paginaFinal" => "984"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22730539"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Minimal residual disease-directed therapy for childhood acute myeloid leukaemia&#58; results of the AML02 multicentre trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;E&#46; Rubnitz"
                            1 => "H&#46; Inaba"
                            2 => "G&#46; Dahl"
                            3 => "R&#46;C&#46; Ribeiro"
                            4 => "W&#46;P&#46; Bowman"
                            5 => "J&#46; Taub"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(10)70090-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2010"
                        "volumen" => "11"
                        "paginaInicial" => "543"
                        "paginaFinal" => "552"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20451454"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical significance of genetic aberrations in secondary acute myeloid leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;D&#46; Milosevic"
                            1 => "A&#46; Puda"
                            2 => "L&#46; Malcovati"
                            3 => "T&#46; Berg"
                            4 => "M&#46; Hofbauer"
                            5 => "A&#46; Stukalov"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ajh.23309"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Hematol"
                        "fecha" => "2012"
                        "volumen" => "87"
                        "paginaInicial" => "1010"
                        "paginaFinal" => "1016"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22887079"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Understanding the molecular pathogenesis of acute promyelocytic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Lo-Coco"
                            1 => "S&#46;K&#46; Hasan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.beha.2014.04.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Best Pract Res Clin Haematol"
                        "fecha" => "2014"
                        "volumen" => "27"
                        "paginaInicial" => "3"
                        "paginaFinal" => "9"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24907012"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Stem cell transplantation in pediatric leukemia and myelodysplasia&#58; state of the art and current challenges"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Bierings"
                            1 => "J&#46;B&#46; Nachman"
                            2 => "C&#46;M&#46; Zwaan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Stem Cell Res Ther"
                        "fecha" => "2007"
                        "volumen" => "2"
                        "paginaInicial" => "53"
                        "paginaFinal" => "63"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18240454"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relapsed and refractory pediatric acute myeloid leukemia&#58; current and emerging treatments"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Davila"
                            1 => "E&#46; Slotkin"
                            2 => "T&#46; Renaud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40272-013-0048-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Paediatr Drugs"
                        "fecha" => "2014"
                        "volumen" => "16"
                        "paginaInicial" => "151"
                        "paginaFinal" => "168"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24158739"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "c-Myc regulates expression of NKG2D ligands ULBP1&#47;2&#47;3 in AML and modulates their susceptibility to NK-mediated lysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46; Nanbakhsh"
                            1 => "C&#46; Pochon"
                            2 => "A&#46; Mallavialle"
                            3 => "S&#46; Amsellem"
                            4 => "J&#46;H&#46; Bourhis"
                            5 => "S&#46; Chouaib"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2013-11-536219"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2014"
                        "volumen" => "123"
                        "paginaInicial" => "3585"
                        "paginaFinal" => "3595"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24677544"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46; Rohner"
                            1 => "U&#46; Langenkamp"
                            2 => "U&#46; Siegler"
                            3 => "C&#46;P&#46; Kalberer"
                            4 => "A&#46; Wodnar-Filipowicz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.leukres.2007.02.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Res"
                        "fecha" => "2007"
                        "volumen" => "31"
                        "paginaInicial" => "1393"
                        "paginaFinal" => "1402"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17391757"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Diermayr"
                            1 => "H&#46; Himmelreich"
                            2 => "B&#46; Durovic"
                            3 => "A&#46; Mathys-Schneeberger"
                            4 => "U&#46; Siegler"
                            5 => "U&#46; Langenkamp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2007-07-101311"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2008"
                        "volumen" => "111"
                        "paginaInicial" => "1428"
                        "paginaFinal" => "1436"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17993609"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "NK cell transplantation as consolidation therapy in children with acute myeloid leukemia-results from a pilot study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "W&#46; Leung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dmcn.13106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Macs &#38; More"
                        "fecha" => "2014"
                        "volumen" => "1"
                        "paginaInicial" => "15"
                        "paginaFinal" => "17"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27017925"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Highlights of the third international conference on immunotherapy in pediatric oncology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Brehm"
                            1 => "S&#46; Huenecke"
                            2 => "V&#46; Pfirrmann"
                            3 => "C&#46; Rossig"
                            4 => "C&#46;L&#46; Mackall"
                            5 => "C&#46;M&#46; Bollard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/08880018.2013.802106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Hematol Oncol"
                        "fecha" => "2013"
                        "volumen" => "30"
                        "paginaInicial" => "349"
                        "paginaFinal" => "366"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23758210"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:3 [
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0110" class="elsevierStylePara elsevierViewall">This study was partially funded by the <span class="elsevierStyleGrantSponsor" id="gs1">Fondo de Investigaci&#243;n Sanitaria</span> &#40;FIS&#44; project PI12&#47;01622&#41;&#44; and the <span class="elsevierStyleGrantSponsor" id="gs2">CRIS Cancer Foundation</span> &#40;<a class="elsevierStyleInterRef" id="intr0010" href="http://www.criscancer.org/es/index.php">http&#58;&#47;&#47;www&#46;criscancer&#46;org&#47;es&#47;index&#46;php</a>&#41;&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23412879/0000008400000004/v1_201603300938/S2341287916000259/v1_201603300938/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "26005"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23412879/0000008400000004/v1_201603300938/S2341287916000259/v1_201603300938/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287916000259?idApp=UINPBA00005H"
]

Article information

ISSN: 23412879
Original language: English

DOI:10.1016/j.anpede.2015.07.028

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	5	9	14
2024 October	38	49	87
2024 September	49	37	86
2024 August	43	64	107
2024 July	40	38	78
2024 June	54	30	84
2024 May	61	31	92
2024 April	47	37	84
2024 March	45	21	66
2024 February	46	24	70
2024 January	41	25	66
2023 December	34	18	52
2023 November	44	26	70
2023 October	47	34	81
2023 September	47	23	70
2023 August	45	24	69
2023 July	106	21	127
2023 June	39	25	64
2023 May	37	25	62
2023 April	33	13	46
2023 March	61	24	85
2023 February	64	12	76
2023 January	26	18	44
2022 December	82	26	108
2022 November	71	41	112
2022 October	54	39	93
2022 September	35	36	71
2022 August	44	38	82
2022 July	44	37	81
2022 June	40	34	74
2022 May	35	34	69
2022 April	47	29	76
2022 March	64	43	107
2022 February	40	33	73
2022 January	38	29	67
2021 December	29	41	70
2021 November	40	44	84
2021 October	49	64	113
2021 September	36	57	93
2021 August	38	40	78
2021 July	37	35	72
2021 June	36	35	71
2021 May	28	29	57
2021 April	136	50	186
2021 March	49	31	80
2021 February	39	25	64
2021 January	30	22	52
2020 December	40	23	63
2020 November	28	21	49
2020 October	35	11	46
2020 September	33	17	50
2020 August	16	13	29
2020 July	29	16	45
2020 June	29	11	40
2020 May	45	15	60
2020 April	41	19	60
2020 March	43	19	62
2020 February	140	13	153
2020 January	73	21	94
2019 December	87	18	105
2019 November	27	16	43
2019 October	32	10	42
2019 September	50	9	59
2019 August	59	21	80
2019 July	23	18	41
2019 June	24	25	49
2019 May	34	12	46
2019 April	62	45	107
2019 March	28	20	48
2019 February	49	24	73
2019 January	38	24	62
2018 December	39	21	60
2018 November	128	36	164
2018 October	163	45	208
2018 September	81	35	116
2018 August	4	0	4
2018 July	1	0	1
2018 June	4	0	4
2018 May	1	0	1
2018 April	16	0	16
2018 March	15	0	15
2018 February	10	0	10
2018 January	13	0	13
2017 December	13	0	13
2017 November	8	0	8
2017 October	10	0	10
2017 September	14	0	14
2017 August	13	0	13
2017 July	14	0	14
2017 June	22	7	29
2017 May	30	15	45
2017 April	14	5	19
2017 March	11	6	17
2017 February	8	6	14
2017 January	5	2	7
2016 December	14	19	33
2016 November	27	16	43
2016 October	37	11	48
2016 September	28	10	38
2016 August	27	5	32
2016 July	15	3	18
2016 April	5	0	5

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter